重组人脑利钠肽对心内科重症监护室心力衰竭患者心功能的影响

Effect of Recombinant Human Brain Natriuretic Peptide on Cardiac Function in Patients with Heart Failure in the Intensive Care Unit of Cardiology

目的探讨重组人脑利钠肽对心内科重症监护室心力衰竭患者的疗效及心功能的影响。方法选取医院心内科重症监护室2021年2月至2023年2月收治的心力衰竭患者55例,按双盲原则分为对照组(27例,常规治疗)和试验组(28例,重组人脑利钠肽治疗)。结果试验组患者治疗优良率为92.86%,显著高于对照组70.37%(P<0.05);试验组的左心室射血分数显著高于对照组(P<0.05),左室收缩末期内径(LVESd)、左室舒张末期内径(LVEDd)、血浆脑利钠肽(BNP)、心率、氨基末端B型利钠肽前体(NT-proBNP)显著低于对照组(P<0.05);对照组和试验组患者不良反应发生率相当(11.11%比17.86%,P>0.05)。结论重组人脑利钠肽治疗心内科重症监护室心力衰竭患者疗效确切,可改善其心功能和血清指标,且安全性好,值得临床推广。

Objective To investigate the therapeutic effect of recombinant human brain natriuretic peptide on cardiac function in heart failure patients in the intensive care unit of cardiology.Methods A total of 55 heart failure patients admitted to the hospital's cardiology intensive care unit from February 2021 to February 2023 were selected and divided into the control group(27 cases,conventional treatment)and the experimental group(28 cases,recombinant human brain natriuretic peptide treatment)according to the double-blind principle.Results The excellent and good treatment rate in the experimental group was 92.86%,which was significantly higher than 70.37%in the control group(P<0.05).The left ventricular ejection fraction in the experimental group was significantly higher than that in the control group(P<0.05),while the left ventricular end systolic diameter(LVESd),left ventricular end diastolic diameter(LVEDd),plasma brain natriuretic peptide(BNP),heart rate,and N-terminal B-type natriuretic peptide precursor(NT-proBNP)in the experimental group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the control group was comparable to that in the experimental group(11.11%vs.17.86%,P>0.05).Conclusion Recombinant human brain natriuretic peptide has a definite therapeutic effect on heart failure patients in the intensive care unit of cardiology.It can improve their cardiac function and serum indicators,and has good safety,which is worthy of clinical promotion.